| Characteristic | Overall N = 123 |
VETC- N = 86 |
VETC+ N = 37 |
p-value1 |
|---|---|---|---|---|
| Age, Mean (SD) | 50.86 (12.13) | 51.55 (11.83) | 49.26 (12.83) | 0.357 |
| Gender, n (%) | 0.179 | |||
| Female | 18 (15%) | 15 (17%) | 3 (8.1%) | |
| Male | 105 (85%) | 71 (83%) | 34 (92%) | |
| HBV infection, n (%) | 101 (82%) | 68 (79%) | 33 (89%) | 0.179 |
| HCV infection, n (%) | 2 (1.6%) | 2 (2.3%) | 0 (0%) | >0.999 |
| ECOG PS, n (%) | 0.340 | |||
| 0 | 105 (85%) | 73 (85%) | 32 (86%) | |
| 1 | 17 (14%) | 13 (15%) | 4 (11%) | |
| 3 | 1 (0.8%) | 0 (0%) | 1 (2.7%) | |
| Post-radical surgery, n (%) | 65 (53%) | 37 (43%) | 28 (76%) | <0.001 |
| Post-immunotherapy, n (%) | 13 (11%) | 7 (8.1%) | 6 (16%) | 0.208 |
| Post-chemotherapy, n (%) | 54 (44%) | 29 (34%) | 25 (68%) | <0.001 |
| Tumor Num, n (%) | 0.948 | |||
| <3 | 17 (14%) | 12 (14%) | 5 (14%) | |
| ≥3 | 106 (86%) | 74 (86%) | 32 (86%) | |
| Tumor Size, n (%) | 0.008 | |||
| <5 | 64 (52%) | 38 (44%) | 26 (70%) | |
| ≥5 | 59 (48%) | 48 (56%) | 11 (30%) | |
| Lymphatic metastasis, n (%) | 63 (51%) | 48 (56%) | 15 (41%) | 0.120 |
| Distant metastasis, n (%) | 82 (67%) | 57 (66%) | 25 (68%) | 0.889 |
| Presentation of PVTT, n (%) | 46 (37%) | 39 (45%) | 7 (19%) | 0.005 |
| BCLC, n (%) | 0.429 | |||
| 0/A | 7 (5.7%) | 4 (4.7%) | 3 (8.1%) | |
| B/C | 116 (94%) | 82 (95%) | 34 (92%) | |
| TNM stage, n (%) | 0.046 | |||
| Ⅰ/Ⅱ | 18 (15%) | 9 (10%) | 9 (24%) | |
| Ⅲ/Ⅳ | 105 (85%) | 77 (90%) | 28 (76%) | |
| AFP, n (%) | 0.172 | |||
| <400 | 68 (55%) | 51 (59%) | 17 (46%) | |
| ≥400 | 55 (45%) | 35 (41%) | 20 (54%) | |
| PIVKA-Ⅱ, n (%) | 0.429 | |||
| <100 | 36 (29%) | 27 (31%) | 9 (24%) | |
| ≥100 | 87 (71%) | 59 (69%) | 28 (76%) | |
| WBC, Median (Q1, Q3) | 6.27 (5.11, 8.07) | 6.59 (5.06, 8.07) | 5.98 (5.40, 7.18) | 0.669 |
| NE, Median (Q1, Q3) | 4.13 (3.04, 5.90) | 4.39 (3.03, 5.95) | 3.94 (3.08, 4.82) | 0.302 |
| LY, Median (Q1, Q3) | 1.52 (1.09, 2.06) | 1.53 (1.07, 2.02) | 1.52 (1.24, 2.10) | 0.593 |
| Platelet, Median (Q1, Q3) | 183.00 (131.00, 248.00) | 185.50 (131.00, 269.00) | 181.00 (132.00, 211.00) | 0.741 |
| NLR, n (%) | 0.271 | |||
| <3.3 | 74 (60%) | 49 (57%) | 25 (68%) | |
| ≥3.3 | 49 (40%) | 37 (43%) | 12 (32%) | |
| PLR, n (%) | 0.094 | |||
| <117 | 59 (48%) | 37 (43%) | 22 (59%) | |
| ≥117 | 64 (52%) | 49 (57%) | 15 (41%) | |
| PT, Median (Q1, Q3) | 12.30 (11.60, 13.10) | 12.35 (11.60, 13.10) | 12.30 (11.60, 12.90) | 0.847 |
| CRP, Median (Q1, Q3) | 9.27 (2.24, 28.02) | 9.44 (2.64, 28.01) | 8.88 (1.77, 28.38) | 0.629 |
| ALT, Median (Q1, Q3) | 42.80 (24.30, 68.60) | 37.65 (24.10, 60.80) | 46.80 (27.90, 81.20) | 0.082 |
| AST, Median (Q1, Q3) | 46.60 (30.60, 76.60) | 48.55 (29.30, 76.60) | 42.10 (34.70, 76.20) | 0.884 |
| TBIL, Median (Q1, Q3) | 13.40 (10.30, 18.20) | 13.30 (10.10, 17.50) | 13.60 (11.60, 18.90) | 0.328 |
| ALB, Median (Q1, Q3) | 42.70 (38.00, 45.20) | 42.45 (37.30, 45.10) | 43.50 (39.90, 46.40) | 0.187 |
| ALBI, n (%) | 0.561 | |||
| 1 | 85 (69%) | 57 (66%) | 28 (76%) | |
| 2 | 36 (29%) | 27 (31%) | 9 (24%) | |
| 3 | 2 (1.6%) | 2 (2.3%) | 0 (0%) | |
| Child-Pugh, n (%) | 0.667 | |||
| 1 | 117 (95%) | 81 (94%) | 36 (97%) | |
| 2 | 6 (4.9%) | 5 (5.8%) | 1 (2.7%) | |
| 1 Welch Two Sample t-test; Pearson’s Chi-squared test; Fisher’s exact test; Kruskal-Wallis rank sum test | ||||